Till the moment, there are no approved antiviral treatments for COVID-19. Saikosaponin A, Saikosaponin B, and Saikosaponin D are major triterpenoid saponins derived from Bupleurum falcatum L. (Umbelliferae) with valuable pharmacological activities. These active components exbibit several immunomodulatory, anti-inflammatory, anti-bacterial, antiviral, and anti-cancer effects. We propose that Saikosaponins might hold the promise for the treatment of COVID-19 based on the following rationale:
-
1.
Saikosaponins exhibit immunomodulatory and anti-inflammatory activities. Saikosaponin A dose-dependently inhibits the production of several inflammatory mediators ROS, TNF-a, COX-2, iNOS, and interleukins (IL-6, IL-8, and IL-10) which are responsible for the cytokine storm of severe COVID-19 patients [1]. Saikosaponin D could exhibit an anti-proliferative effect in activated T-lymphocyte, in part via suppression of the nucleotide-binding oligomerization domain 2 (NOD2)/NF-κB, NF-AT, and AP-1 MAPK signaling, which plays a role in the severity and mortality of COVID-19 [2].
-
2.
Saikosaponins exhibited antiviral activities against several types of viruses in experimental studies. Saikosaponin A inhibited influenza A virus and reduced lung immunopathology. Saikosaponin B demonstrated in-vitro antiviral activity against HCoV-229E by inhibiting the viral attachment to cells in a dose-dependent manner, blocking the viral penetration into cells, and interfering with the early stage of viral replication, such as virus absorption and penetration [3]. Saikosaponin D inhibits the autophagic activity of Enterovirus A71.
-
3.
A molecular docking study demonstrated that Saikosaponin A has a high affinity to bind to a target receptor of the SARS-CoV-2, ACE II receptor [4].
In conclusion, we believe that Saikosaponins are candidate treatment for COVID-19 owing to their anti-inflammatory, immunomodulatory, and antiviral activities. We recommend future well-designed randomized controlled trials to evaluate the safety and efficacy of Saikosaponins in patients with COVID-19.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.mehy.2020.109782.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
References
- 1.Yuan B., Yang R., Ma Y., Zhou S., Zhang X., Liu Y. A systematic review of the active saikosaponins and extracts isolated from radix bupleuri and their applications. Pharm Biol. 2017;55:620–635. doi: 10.1080/13880209.2016.1262433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Yang H., Chen X., Jiang C., He K., Hu Y. Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients. J Vet Res. 2017;61:405–410. doi: 10.1515/jvetres-2017-0062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Cheng P.-W., Ng L.-T., Chiang L.-C., Lin C.-C. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol. 2006;33:612–616. doi: 10.1111/j.1440-1681.2006.04415.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Yan Y.-M., Shen X., Cao Y.-K., Zhang J.-J., Wang Y., Cheng Y.-X. Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening. Preprints. 2020 doi: 10.20944/preprints202002.0254.v1. [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.